文献速递核素与放射性配体治疗肿瘤 PET/CT

支气管与胃肠胰神经内分泌肿瘤的177Lu-DOTATATE挽救性PRRT

Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-09-28

本研究纳入进展性支气管或胃肠胰神经内分泌肿瘤患者,在初始PRRT获益且PFS≥18个月后行挽救性PRRT,再治疗累积剂量14.8 GBq/2周期。R-PRRT后客观缓解15.5%、疾病稳定59.5%,中位PFS 14.6个月;III/IV级骨髓毒性6.6%,AML/MDS总发生率2.2%,无PRRT相关III/IV级肾毒性。

要点

  • 挽救性PRRT后R-PRRT客观缓解15.5%、疾病稳定59.5%,中位PFS 14.6个月。
  • R-PRRT与RR-PRRT后III/IV级骨髓毒性分别为6.6%和7.7%。
  • AML/MDS总发生率2.2%,未观察到PRRT相关III/IV级肾毒性。

核心结论

  • 对初始PRRT后进展(relapse-PD)的患者,累积剂量至60.5 GBq的177Lu-DOTATATE挽救性PRRT安全有效。
  • 安全性似乎与初始PRRT相似,未观察到AML或MDS发生率升高。
  • 再治疗后未发生III/IV级肾毒性。

研究设计与样本

  • 本研究为单中心研究,纳入进展性支气管NET或GEP-NET患者。
  • 患者若从初始PRRT获益且PFS至少18个月,则入选再治疗。
  • 每次再治疗接受额外累积剂量14.8 GBq的177Lu-DOTATATE,分两个周期。
  • 安全性分析纳入181例患者,疗效分析纳入168例患者。
  • 中位随访88.6个月(95%CI 79.0-98.2)。

主要发现

  • R-PRRT(168例)后最佳疗效为客观缓解26例(15.5%)、疾病稳定100例(59.5%)。
  • RR-PRRT(13例)后最佳疗效为客观缓解5例(38.5%)、疾病稳定7例(53.8%)。
  • R-PRRT后中位PFS为14.6个月(95%CI 12.4-16.9),RR-PRRT后为14.2个月(95%CI 9.8-18.5)。
  • 初始PRRT加R-PRRT及RR-PRRT后联合中位OS为80.8个月(95%CI 66.0-95.6)。
  • 与未随机对照相比,挽救治疗使支气管NET、GEP-NET及中肠NET患者的OS显著延长。

关键数值与推荐

  • R-PRRT期间中位累积剂量为44.7 GBq(范围26.3-46.4 GBq,168例)。
  • RR-PRRT期间中位累积剂量为59.7 GBq(范围55.2-≤60.5 GBq,13例)。
  • R-PRRT后III/IV级骨髓毒性发生率为6.6%,RR-PRRT后为7.7%。
  • AML和MDS总发生率为2.2%。
  • 未观察到PRRT相关III/IV级肾毒性。

临床怎么用

  • 对初始PRRT获益且PFS≥18个月的进展性支气管NET或GEP-NET患者,可考虑挽救性177Lu-DOTATATE治疗。
  • 挽救方案为额外累积剂量14.8 GBq,分两个周期给药。
  • 累积剂量至60.5 GBq的挽救性PRRT在本研究中显示安全有效。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Therapy with [177Lu-DOTA,Tyr3]octreotate is effective in patients with grade I/II metastasized and/or inoperable bronchial neuroendocrine tumour (NET) or gastroenteropancreatic NET (GEP-NET). In this study, we investigated the efficacy and safety of salvage treatment with [177Lu-DOTA,Tyr3]octreotate. METHODS: Patients with progressive bronchial NET or GEP-NET were selected for re-(re)treatment if they had benefited from initial peptide receptor radionuclide therapy (I-PRRT) with a minimal progression-free survival (PFS) of 18 months. Patients received an additional cumulative dose of 14.8 GBq of [177Lu-DOTA,Tyr3]octreotate over two cycles per retreatment with PRRT (R-PRRT) or re-retreatment with PRRT (RR-PRRT). RESULTS: The safety and efficacy analyses included 181 patients and 168 patients, respectively, with bronchial NET or GEP-NET. Overall median follow-up was 88.6 months (95% CI 79.0-98.2). Median cumulative doses were 44.7 GBq (range 26.3-46.4 GBq) during R-PRRT (168 patients) and 59.7 GBq (range 55.2-≤60.5 GBq) during RR-PRRT (13 patients). Objective response and stable disease, as best response, were observed in 26 patients (15.5%) and 100 patients (59.5%) following R-PRRT, and in 5 patients (38.5%) and 7 patients (53.8%) following RR-PRRT, respectively. Median PFS was 14.6 months (95% CI 12.4-16.9) following R-PRRT and 14.2 months (95% CI 9.8-18.5) following RR-PRRT. Combined overall survival (OS) after I-PRRT plus R-PRRT and RR-PRRT was 80.8 months (95% CI 66.0-95.6). Grade III/IV bone marrow toxicity occurred in 6.6% and 7.7% of patients after R-PRRT and RR-PRRT, respectively. Salvage therapy resulted in a significantly longer OS in patients with bronchial NET, GEP-NET and midgut NET than in a nonrandomized control group. The total incidence of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) was 2.2%. No PRRT-related grade III/IV nephrotoxicity was observed. CONCLUSION: A cumulative dose of up to 60.5 GBq salvage PRRT with [177Lu-DOTA,Tyr3]octreotate is safe and effective in patients with progressive disease (relapse-PD) following I-PRRT with [177Lu-DOTA,Tyr3]octreotate. Safety appears similar to that of I-PRRT as no higher incidence of AML or MDS was observed. No grade III/IV renal toxicity occurred after retreatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2018. PMID: 30267116. doi:10.1007/s00259-018-4158-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。